Uncategorized

Johnson & Johnson announced a proposed Plan of Reorganization by its subsidiary, LLT Management LLC, for the comprehensive and final resolution of all current and future claims related to ovarian cancer arising from cosmetic talc litigation against it and its affiliates in the United States.

Pfizer Inc. reported financial results for the first quarter of 2024 and raised its Adjusted diluted EPS guidance while maintaining all other components of its 2024 financial guidance.

United Therapeutics Corporation, a public benefit corporation, announced its financial results for the quarter ended March 31, 2024.

Bio-Techne Corporation reported its financial results for the third quarter ending March 31, 2024.

Poolbeg Pharma announces that, further to its announcement on20 March 2024,the Company has received the fully granted patent from the US Patent Office for its Immunomodulator II patent application.

Epsilogen, a global leader in the development of immunoglobulin E antibodies to treat cancer, announces the appointments of Ashley Nagle as Chief Business Officer and Peter Finan, currently a Non-Executive Director, as Non-Executive Chairman.

Ellipses Pharma Limited announced the U.S. Food and Drug Administration has confirmed the company’s next generation selective RET inhibitor, EP0031/A400, is clear to progress into Phase 2 clinical development.

Tessellate BIO announces the appointment of Professor Sandra Strauss, University College London, to its Scientific Advisory Board.

Jacobio Pharma announced that the data from the Phase II registrational study of the KRAS G12C inhibitor glecirasib were offically reported at the April ASCO Plenary Series, which was held online.

Pharma CEOs claim lifesaving drugs wouldn’t be possible without high prices — an assertion that doesn’t stand up to scrutiny.